Treatment of acute myelogenous leukemia in the elderly

R. E. Champlin, J. L. Gajewski, D. W. Golde

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Current data indicate that most elderly patients with acute myelogenous leukemia should be treated with intensive chemotherapy. Most should receive remission induction chemotherapy using cytarabine 100 to 200 mg/m2/d by constant intravenous infusion for five to seven days plus daunorubicin ≥ 30 mg/m2/d for three days. Patients in good overall condition with a near-normal performance status may benefit from a more intensive regimen. Patients achieving remission should receive one to three courses of consolidation chemotherapy. Highly debilitated patients have poor results with any form of therapy, and there has been no apparent advantage for low-dose chemotherapy compared to standard treatment regimens. The intensity of chemotherapy must be individualized to the requirements of the patients.

Original languageEnglish (US)
Pages (from-to)51-56
Number of pages6
JournalSeminars in Oncology
Volume16
Issue number1
StatePublished - 1989
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Drug Therapy
Consolidation Chemotherapy
Therapeutics
Remission Induction
Induction Chemotherapy
Daunorubicin
Cytarabine
Intravenous Infusions

ASJC Scopus subject areas

  • Oncology

Cite this

Champlin, R. E., Gajewski, J. L., & Golde, D. W. (1989). Treatment of acute myelogenous leukemia in the elderly. Seminars in Oncology, 16(1), 51-56.

Treatment of acute myelogenous leukemia in the elderly. / Champlin, R. E.; Gajewski, J. L.; Golde, D. W.

In: Seminars in Oncology, Vol. 16, No. 1, 1989, p. 51-56.

Research output: Contribution to journalArticle

Champlin, RE, Gajewski, JL & Golde, DW 1989, 'Treatment of acute myelogenous leukemia in the elderly', Seminars in Oncology, vol. 16, no. 1, pp. 51-56.
Champlin RE, Gajewski JL, Golde DW. Treatment of acute myelogenous leukemia in the elderly. Seminars in Oncology. 1989;16(1):51-56.
Champlin, R. E. ; Gajewski, J. L. ; Golde, D. W. / Treatment of acute myelogenous leukemia in the elderly. In: Seminars in Oncology. 1989 ; Vol. 16, No. 1. pp. 51-56.
@article{3bc418876b624c8697db9de3aaf1946a,
title = "Treatment of acute myelogenous leukemia in the elderly",
abstract = "Current data indicate that most elderly patients with acute myelogenous leukemia should be treated with intensive chemotherapy. Most should receive remission induction chemotherapy using cytarabine 100 to 200 mg/m2/d by constant intravenous infusion for five to seven days plus daunorubicin ≥ 30 mg/m2/d for three days. Patients in good overall condition with a near-normal performance status may benefit from a more intensive regimen. Patients achieving remission should receive one to three courses of consolidation chemotherapy. Highly debilitated patients have poor results with any form of therapy, and there has been no apparent advantage for low-dose chemotherapy compared to standard treatment regimens. The intensity of chemotherapy must be individualized to the requirements of the patients.",
author = "Champlin, {R. E.} and Gajewski, {J. L.} and Golde, {D. W.}",
year = "1989",
language = "English (US)",
volume = "16",
pages = "51--56",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Treatment of acute myelogenous leukemia in the elderly

AU - Champlin, R. E.

AU - Gajewski, J. L.

AU - Golde, D. W.

PY - 1989

Y1 - 1989

N2 - Current data indicate that most elderly patients with acute myelogenous leukemia should be treated with intensive chemotherapy. Most should receive remission induction chemotherapy using cytarabine 100 to 200 mg/m2/d by constant intravenous infusion for five to seven days plus daunorubicin ≥ 30 mg/m2/d for three days. Patients in good overall condition with a near-normal performance status may benefit from a more intensive regimen. Patients achieving remission should receive one to three courses of consolidation chemotherapy. Highly debilitated patients have poor results with any form of therapy, and there has been no apparent advantage for low-dose chemotherapy compared to standard treatment regimens. The intensity of chemotherapy must be individualized to the requirements of the patients.

AB - Current data indicate that most elderly patients with acute myelogenous leukemia should be treated with intensive chemotherapy. Most should receive remission induction chemotherapy using cytarabine 100 to 200 mg/m2/d by constant intravenous infusion for five to seven days plus daunorubicin ≥ 30 mg/m2/d for three days. Patients in good overall condition with a near-normal performance status may benefit from a more intensive regimen. Patients achieving remission should receive one to three courses of consolidation chemotherapy. Highly debilitated patients have poor results with any form of therapy, and there has been no apparent advantage for low-dose chemotherapy compared to standard treatment regimens. The intensity of chemotherapy must be individualized to the requirements of the patients.

UR - http://www.scopus.com/inward/record.url?scp=0024516953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024516953&partnerID=8YFLogxK

M3 - Article

C2 - 2645650

AN - SCOPUS:0024516953

VL - 16

SP - 51

EP - 56

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1

ER -